Takeda Pharmaceutical (TAK) said on Thursday that it will invest about ¥100B to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan.The Japanese.
Investing in a new production facility and carbon net-zero warehouse in Belgium, Takeda aims to expand access for rare and complex chronic disease treatments.